Stockscreener 앱 받기
7.94
2.34%
-0.19
시간 외 거래:
7.97
0.03
+0.38%
전일 마감가:
$8.13
열려 있는:
$8.11
하루 거래량:
1.28M
Relative Volume:
0.90
시가총액:
$473.28M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-2.5644
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
-15.08%
1개월 성능:
+1.79%
6개월 성능:
+182.56%
1년 성능:
+108.40%
1일 변동 폭
$7.7696
$8.255
1주일 범위
$7.7696
$9.55
52주 변동 폭
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
7.94 | 484.60M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Trendlines Converge — Decision Point for The Ruby Mills LimitedAnalyst Downgrades & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
Twin Insider Buys Signal Major Confidence in Kyverna Therapeutics - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares - MarketBeat
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock - MarketBeat
Kyverna Therapeutics director Seidenberg buys $999,997 in shares By Investing.com - Investing.com Nigeria
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 By Investing.com - Investing.com Australia
Kyverna Therapeutics director Seidenberg buys $999,997 in shares - Investing.com
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 - Investing.com
Kyverna Therapeutics Insider Bought Shares Worth $999,998, According to a Recent SEC Filing - marketscreener.com
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 11.68% to 28.76 - Nasdaq
Will Kyverna Therapeutics Inc. stock recover faster than peers2025 EndofYear Setup & Verified Swing Trading Watchlists - Улправда
Institution Moves: What margin trends mean for Kyverna Therapeutics Inc. stockForecast Cut & Community Trade Idea Sharing - ulpravda.ru
Why Kyverna Therapeutics Inc. stock is rated strong buy2025 Market Outlook & Weekly Stock Breakout Alerts - Улправда
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Kyverna Therapeutics Inc. stock attractive after correction2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Market Leaders: What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Pullbacks & Accurate Buy Signal Alerts - ulpravda.ru
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Is Kyverna Therapeutics Inc. stock near bottom after declineGDP Growth & Growth Focused Stock Pick Reports - DonanımHaber
Kyverna Therapeutics announces $100 million public offering - MSN
Is Kyverna Therapeutics Inc. stock attractive after correctionDollar Strength & Daily Stock Trend Reports - ulpravda.ru
What is the fair value of Kyverna Therapeutics Inc. stock nowMarket Volume Summary & Real-Time Market Sentiment Alerts - DonanımHaber
Will Kyverna Therapeutics Inc. stock see PE expansionQuarterly Growth Report & Fast Moving Trade Plans - DonanımHaber
Aug PostEarnings: How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Highlights & High Accuracy Investment Signals - ulpravda.ru
What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Earnings & High Yield Equity Trading Tips - Улправда
How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Snapshot & Low Risk High Win Rate Picks - ulpravda.ru
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies (NASDAQ:KYTX) - Seeking Alpha
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects - Yahoo Finance
Kyverna Therapeutics Announces $100 Million Public Offering - TipRanks
Kyverna Therapeutics Signs Underwriting Agreement With J.P. Morgan, Leerink Partners and Morgan Stanley - TradingView — Track All Markets
Kyverna Therapeutics (NASDAQ:KYTX) CTO Karen Marie Walker Sells 23,998 Shares - MarketBeat
Kyverna Therapeutics CTO Karen Marie Walker Sells Shares - TradingView — Track All Markets
Officer Walker Sells 23,998 ($292.8K) Of Kyverna Therapeutics Inc [KYTX] - TradingView — Track All Markets
Kyverna Therapeutics Shares Drop After Public Offering - StocksToTrade
Kyverna Therapeutics stock plunges after $100 million share offering By Investing.com - Investing.com Nigeria
Kyverna Therapeutics stock plunges after $100 million share offering - Investing.com India
Transcript : Kyverna Therapeutics, Inc.Special Call - marketscreener.com
Kyverna Therapeutics announces pricing of $100M public offering - MSN
Kyverna Therapeutics prices public offering of common stock at $7.50 - Investing.com
Kyverna Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
Kyverna Therapeutics announces pricing of $100 million public offering - marketscreener.com
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):